Guard Therapeutics International Management
Management criteria checks 1/4
Guard Therapeutics International's CEO is Tobias Agervald, appointed in Jan 2019, has a tenure of 5.67 years. directly owns 0.21% of the company’s shares, worth €62.31K. The average tenure of the management team and the board of directors is 4 years and 2.5 years respectively.
Key information
Tobias Agervald
Chief executive officer
n/a
Total compensation
CEO salary percentage | n/a |
CEO tenure | 5.7yrs |
CEO ownership | 0.2% |
Management average tenure | 4yrs |
Board average tenure | 2.5yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Jun 30 2024 | n/a | n/a | -SEK 79m |
Mar 31 2024 | n/a | n/a | -SEK 88m |
Dec 31 2023 | n/a | n/a | -SEK 113m |
Sep 30 2023 | n/a | n/a | -SEK 137m |
Jun 30 2023 | n/a | n/a | -SEK 146m |
Mar 31 2023 | n/a | n/a | -SEK 134m |
Dec 31 2022 | SEK 5m | SEK 2m | -SEK 113m |
Sep 30 2022 | n/a | n/a | -SEK 95m |
Jun 30 2022 | n/a | n/a | -SEK 97m |
Mar 31 2022 | n/a | n/a | -SEK 88m |
Dec 31 2021 | SEK 4m | SEK 2m | -SEK 82m |
Sep 30 2021 | n/a | n/a | -SEK 69m |
Jun 30 2021 | n/a | n/a | -SEK 47m |
Mar 31 2021 | n/a | n/a | -SEK 44m |
Dec 31 2020 | SEK 3m | SEK 1m | -SEK 40m |
Sep 30 2020 | n/a | n/a | -SEK 43m |
Jun 30 2020 | n/a | n/a | -SEK 39m |
Mar 31 2020 | n/a | n/a | -SEK 41m |
Dec 31 2019 | SEK 4m | SEK 1m | -SEK 45m |
Compensation vs Market: Insufficient data to establish whether Tobias's total compensation is reasonable compared to companies of similar size in the German market.
Compensation vs Earnings: Tobias's compensation has increased whilst the company is unprofitable.
CEO
Tobias Agervald (48 yo)
5.7yrs
Tenure
SEK 5,230,000
Compensation
Mr. Tobias Larsson Agervald has been Chief Executive Officer at Guard Therapeutics International AB (publ) (formerly known as A1M Pharma AB (publ))since January 15, 2019 and served as its Chief Medical Off...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Chief Executive Officer | 5.7yrs | SEK 5.23m | 0.21% SEK 62.3k | |
Chief Financial Officer | 4yrs | no data | 0.024% SEK 7.1k | |
C.S.O | 5.3yrs | no data | no data | |
Head of Preclinical Science | 4.1yrs | no data | no data | |
Head of Clinical Operations | 3.3yrs | no data | 0.016% SEK 4.8k | |
Chief Medical Officer | 2.7yrs | no data | no data | |
Head of Chemistry | 2.3yrs | no data | 0.0017% SEK 496.0 |
4.0yrs
Average Tenure
51yo
Average Age
Experienced Management: 5LH0's management team is considered experienced (4 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Independent Chairman of the board | 3.3yrs | SEK 271.00k | 0.052% SEK 15.6k | |
Director | less than a year | no data | no data | |
Member of Scientific Board | no data | no data | no data | |
Non-Executive Independent Director | 5.3yrs | SEK 162.00k | 0.011% SEK 3.4k | |
Non-Executive Independent Director | 1.8yrs | SEK 7.00k | no data | |
Member of Scientific Board | no data | no data | no data | |
Member of Scientific Board | no data | no data | no data | |
Member of Scientific Board | no data | no data | no data | |
Member of Scientific Board | no data | no data | no data | |
Non-Executive Independent Director | 5.3yrs | SEK 162.00k | 0.050% SEK 14.9k | |
Director | less than a year | no data | no data | |
Member of Scientific Board | no data | no data | no data |
2.5yrs
Average Tenure
59yo
Average Age
Experienced Board: 5LH0's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.